Viaskin Peanut Patch Shows promise in Desensitizing Children to Peanut Allergies
Table of Contents
Positive phase 3 trial data from teh VITESSE study are reshaping the approach to managing peanut allergies in young children, moving beyond strict avoidance towards potential desensitization.The study demonstrated that epicutaneous immunotherapy (EPIT) using the Viaskin peanut patch led to statistically notable desensitization in children aged 4 to 7 years after 12 months of treatment.
VITESSE Trial Results
The VITESSE trial revealed that 46.6% of children treated with the Viaskin peanut patch met the pre-defined responder criteria at the 12-month mark, compared to 14.8% of children receiving a placebo. Responders exhibited clinically meaningful increases in the amount of peanut protein they could tolerate during double-blind, placebo-controlled food challenges. The difference in response rates was 31.8%, significantly exceeding the pre-specified efficacy threshold (P < 0.001).Importantly, the safety profile of the patch remained consistent with previous studies, with most adverse events being mild to moderate local skin reactions at the application site, and no treatment-related serious adverse events reported.
Expert Perspective
Dr. David Fleischer, professor of pediatrics at Children’s Hospital Colorado and global principal investigator of the VITESSE trial, emphasized the meaning of the observed desensitization levels, given the low dose of allergen delivered through the skin. He stated that approximately 50% of patients reached the primary endpoint of desensitization, demonstrating a ample increase in peanut tolerance after a year of therapy. “The amount of peanut they tolerated before the therapy increased after a year of therapy, and about 50% of those patients significantly, showing that the therapy really is a safe and effective therapy,” Dr. Fleischer noted.
Shifting Goals in Peanut Allergy Management
The trial focused on children who reacted to 150 mg of peanut protein or less, a group at risk of reactions from even trace amounts of peanut exposure. Dr.Fleischer highlighted that many families aren’t necessarily seeking to incorporate peanut into their diets, but rather to mitigate the severity of accidental reactions. “There are a lot of patients that just wont the protection of desensitization,” he explained. “They don’t want to eat the peanut. They just want to know, if they accidentally eat peanut, do they have a less severe reaction or no reaction at all?”
Long-Term Outlook and Early Intervention
While long-term outcomes are still under examination – most immunotherapy studies follow patients for 3 to 5 years – the importance of managing expectations is crucial.Immunotherapy is a long-term process, requiring patience and consistent treatment. Though, earlier intervention appears to be beneficial, with younger children generally responding more effectively to immunotherapy. This understanding informed the growth of the Viaskin program. “The earlier you start, the better you can get these patients going,” Dr. Fleischer added, suggesting that some children may achieve full tolerance, while others may require continued therapy for ongoing protection.
Regulatory Progress
DBV Technologies has reported that a US Biologics License Application (BLA) submission for the Viaskin peanut patch remains on track for the first half of 2026. This submission will be a critical step in potentially bringing this new treatment option to families affected by peanut allergies.
Reference: